HCC

Although immune checkpoint inhibition–related hepatotoxicity is a rare occurrence, it leads to ICI treatment discontinuation in more than two-thirds of affected patients, according to the results of a retrospective study presented at the American Association for the Study of Liver Diseases’ 2018 Liver Meeting.

Using regorafenib after hepatocellular carcinoma progression on sorafenib in the post–liver transplantation setting produced overall survival effects similar to those of patients without liver transplant, according to results presented at the American Association for the Study of Liver Diseases’ 2018 Liver Meeting.

A look back at all the FDA news in oncology from the month of January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

The combination of sorafenib and modified FOLFOX demonstrated encouraging efficacy in a small phase II study, but some patients exhibited moderate hepatoxicity, according to investigators from the Massachusetts General Hospital Cancer Center.

General Cancer

Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.

Ahmed Omar Kaseb, MD, discusses the role of immunotherapy in the treatment landscape of HCC and the impact it could have in the presurgical setting.

Achieving an objective response to TKI therapy was associated with longer overall survival in patients with previously untreated hepatocellular carcinoma, according to findings of a retrospective analysis presented during the 2019 Gastrointestinal Cancers Symposium.

Cabozantinib has been approved by the FDA for the treatment of patients with hepatocellular carcinoma who previously received sorafenib, Exelixis, the company developing the agent, announced today.